Study outcomes
The primary efficacy endpoint was evaluated in an assessor‐blinded fashion after 6 (facultative visit) and 12 weeks by a panel of six dermatologist (GFM‐O‐Trial Investigator Group) through the global assessment score (GAS), a 7‐point score from −3 (severe worsening) to +3 (excellent improvement) performed using standardized global photographs, taken with the head in a stereotactic positioning device.The second endpoints were represented by the global clinical efficacy and the global tolerability evaluated by the investigators after 12 weeks through a 5‐point score from −2 (very negative) to +2 (very positive). The global clinical efficacy was also evaluated by patients through a 5‐point score from −2 (severe worsening) to +2 (excellent improvement). The patients also evaluated the acceptability and tolerability of the products using a scale from 1 (very accepted) to 10 (not accepted).